ClinicalTrials.gg
Enrolling by invitationNCT06762743BEUpdated Jan 8, 2025

Bioequivalence Study of Two Brivaracetam Oral Solutions in Healthy Adults Under Fasting and High-Fat Meal Conditions

A Phase 1 interventional study of Brivaracetam Oral Solution (Test Formulation) and Brivaracetam Oral Solution (Reference Formulation) in Epilepsy (treatment Refractory), sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-08.

Sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Planned enrollment
22nd of 34
60 · median 94
Started
2024
with 1 other
Phase 1
6 of 34
1 open now
Registered
33rd of 34
by date
Lead sponsor
1 of 34
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 22nd largest by planned enrollment, is one of 2 that started in 2024, is one of 6 in phase 1, and was the 33rd registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the bioequivalence of Brivaracetam oral solution under fasting and high-fat meal conditions in healthy adults. The study will compare a test formulation (produced by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., 300ml: 3g) to the reference formulation (Briviact®, UCB Pharma S.A., 300ml: 3g).

The main questions it aims to answer are:

  1. Do the test and reference formulations of Brivaracetam oral solution exhibit similar pharmacokinetic behavior in the body?
  2. What are the clinical safety outcomes for participants taking the test and reference formulations?

Participants will:

Be randomly assigned to two treatment sequences (T-R or R-T) in a 1:1 ratio. Receive either the test formulation or reference formulation of Brivaracetam oral solution (10ml), taken with 240mL of warm water, under either fasting or high-fat meal conditions.

Cross over to the alternate formulation after a 7-day washout period, completing a total of two treatment periods (2 weeks).

Undergo regular checkups and tests to monitor pharmacokinetics and safety outcomes.

03

Conditions studied

  • Epilepsy (treatment Refractory)

Browse trials for

Keywords

  • crossover
  • bioequivalence
  • Brivaracetam Oral Solution
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age and Gender: Healthy male and female participants aged 18-55 years (inclusive).
  • Weight and : Male participants must weigh ≥50 kg, and females ≥45 kg, with a body mass index (BMI) between 19 and 26. BMI is calculated as: BMI = weight (kg) / height (m²).
  • Participants must fully understand the purpose, methods, content, and test drugs of this study before enrollment, be capable of good communication with investigators, adhere to study requirements, and voluntarily sign the form.
  • Participants must commit to avoiding pregnancy and refraining from sperm/egg donation from the time of consent through 3 months after the last dose. Participants must agree to use effective (non-pharmacological methods) during the trial. Female participants must have had no unprotected sexual activity within 14 days before the first dose.

Exclusion criteria

Exclusion Criteria:

  • History of allergies (e.g., angioedema, anaphylactic shock) or (e.g., to pollen, two or more drugs/foods), or known allergy to briciclib or its .
  • Past or current illnesses that may affect drug absorption, distribution, metabolism, excretion, or the interpretation of safety data, or conditions reducing compliance, including but not limited to gastrointestinal, renal, hepatic, pulmonary, neurological, hematological, endocrine, oncological, immunological, psychiatric, or cardiovascular diseases, as judged by the investigator.
  • Major surgery within 3 months prior to screening or planned surgery during the study period, including procedures affecting pharmacokinetics (e.g., gallbladder/biliary tract surgery).
  • History of significant bleeding, active bleeding, thrombocytopenia, coagulation disorders, or family history of coagulopathy.
  • Vaccination within 28 days prior to screening or planned vaccination during the study.
  • History of substance abuse or dependence within the past 5 years or use of drugs such as morphine, methamphetamine, ketamine, cannabis, or ecstasy within 6 months before screening. Positive urine drug screen results are also exclusionary.
  • Difficulty with venipuncture, intolerance to venous puncture, or history of needle or blood phobia.
  • Lactose intolerance.
  • Special dietary requirements that cannot align with standardized study diets.
  • Participation in any clinical trial and drug administration within 3 months prior to screening.
  • Blood donation or significant blood loss (≥400 mL) within 3 months prior to screening (excluding physiological blood loss in women) or intention to donate blood during the study.
  • Regular smokers (≥5 cigarettes/day) or habitual betel nut chewers within 3 months prior to screening, or inability to abstain from tobacco products during the study.
  • Frequent alcohol consumption (more than 14 units per week, where 1 unit = 360 mL beer, 45 mL spirits, or 150 mL wine) within 3 months prior to screening, positive breath alcohol test, or inability to abstain from alcohol during the study.
  • Excessive intake of tea, coffee, caffeine-containing products, grapefruit, or xanthine-rich foods or beverages (e.g., theophylline, caffeine, theobromine) averaging more than 8 cups/day (1 cup = 200 mL) within 3 months prior to screening or inability to discontinue such intake during the study.
  • Use of any medications, including prescription, over-the-counter drugs, herbal medicines, or health supplements, within 14 days prior to the first dose.
  • Use of any liver enzyme-altering drugs within 28 days prior to the first dose.
  • Pregnant or lactating women, or females with positive pregnancy tests.
  • Positive results for any of the following virological tests: surface antigen, antibody, antibody, or syphilis antibody.
  • abnormalities in physical examination, vital signs, 12-lead , or laboratory tests at screening, as determined by the investigator.
  • Other reasons that may prevent the participant from completing the study, or any other factors deemed unsuitable for participation by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Fasting group

    Participants in fasting group will first receive a single oral dose of the test formulation of Brivaracetam oral solution in the first period, followed by a washout period, and then a single oral dose of the reference formulation of Brivaracetam oral solution in the second period.

    Drug: Brivaracetam Oral Solution (Test Formulation) · Drug: Brivaracetam Oral Solution (Reference Formulation)

  • Experimental
    High-fat meal group

    Participants will first receive a single oral dose of the reference formulation of Brivaracetam oral solution in the first period, followed by a washout period, and then a single oral dose of the test formulation of Brivaracetam in the second period.

    Drug: Brivaracetam Oral Solution (Test Formulation) · Drug: Brivaracetam Oral Solution (Reference Formulation)

Interventions

  • The drug is manufactured by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.

  • The drug is manufactured by UCB Pharma S.A. under the trade name Briviact®. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.

    Also known as: Briviact®

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Cmax is the maximum observed plasma concentration of the drug following a single oral dose. This parameter reflects the peak exposure to the drug in the bloodstream after administration.

    Time frame: two weeks

  2. Area Under the Plasma Concentration-Time Curve from Time 0 to Last Measurable Concentration (AUC0-t)

    AUC0-t represents the total drug exposure from time 0 to the last measurable concentration. It is an important pharmacokinetic parameter for understanding the extent of drug absorption over time.

    Time frame: two weeks

  3. Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity (AUC0-∞)

    AUC0-∞ is the area under the plasma concentration-time curve from time 0 to infinity, capturing the total exposure to the drug. It includes all measurable concentrations, both during and after the absorption phase.

    Time frame: two weeks

Secondary outcomes

  1. Time to Reach Maximum Plasma Concentration(Tmax )

    Tmax is the time it takes to reach the maximum plasma concentration (Cmax) after a single dose of the drug. It indicates the rate at which the drug is absorbed into the bloodstream.

    Time frame: two weeks

  2. Terminal Elimination Rate Constant (λz)

    λz is the terminal elimination rate constant, which is used to describe the rate at which the drug is cleared from the body during the elimination phase. This value helps estimate the half-life of the drug.

    Time frame: two weeks

  3. Half-life (t1/2)

    t1/2 is the time required for the plasma concentration of the drug to decrease by half. It is a key pharmacokinetic parameter to understand the duration of action of the drug.

    Time frame: two weeks

  4. Percentage of the Area Under the Curve Extrapolated to Infinity(AUC_%Extrap )

    AUC_%Extrap is the percentage of the total AUC that is extrapolated beyond the last measured concentration (AUC∞ - AUC0-t) / AUC∞. This indicates the reliability of the AUC data and how much data is based on extrapolated values.

    Time frame: two weeks

07

Study locations

1 site
08

References and documents

Publications

  • Velazquez J, Acosta J, Herrera N, Morales A, Gonzalez O, Herrera F, Estrada MP, Carpio Y. Novel IFNgamma homologue identified in Nile tilapia (Oreochromis niloticus) links with immune response in gills under different stimuli. Fish Shellfish Immunol. 2017 Dec;71:275-285. doi: 10.1016/j.fsi.2017.10.014. Epub 2017 Oct 7. PubMed 29017941 ↗
  • Aranake A, Mashour GA, Avidan MS. Minimum alveolar concentration: ongoing relevance and clinical utility. Anaesthesia. 2013 May;68(5):512-22. doi: 10.1111/anae.12168. Epub 2013 Feb 16. PubMed 23414556 ↗
  • Cho SY, Kwon YK, Nam M, Vaidya B, Kim SR, Lee S, Kwon J, Kim D, Hwang GS. Integrated profiling of global metabolomic and transcriptomic responses to viral hemorrhagic septicemia virus infection in olive flounder. Fish Shellfish Immunol. 2017 Dec;71:220-229. doi: 10.1016/j.fsi.2017.10.007. Epub 2017 Oct 7. PubMed 29017947 ↗
  • Tsilidis KK, Panagiotou OA, Sena ES, Aretouli E, Evangelou E, Howells DW, Al-Shahi Salman R, Macleod MR, Ioannidis JP. Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol. 2013 Jul;11(7):e1001609. doi: 10.1371/journal.pbio.1001609. Epub 2013 Jul 16. PubMed 23874156 ↗
  • Zhu M, Tao Y, Pu J, Zhao H, Wan L, Zhang P, Tang C. Pharmacokinetics and Bioequivalence of Fudosteine in Healthy Chinese Volunteers Under Fasting and Fed Conditions: A 4-Way Replicate Crossover Study. Clin Pharmacol Drug Dev. 2023 Jan;12(1):30-37. doi: 10.1002/cpdd.1137. Epub 2022 Jul 6. PubMed 35794358 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Start Date: IPD and supporting information will be available starting from the publication of the primary study results. End Date: IPD and supporting information will be available for a period of five years following the study's completion and publication. After this period, access may be restricted or subject to specific conditions.

Access criteria: Qualified researchers, including academic institutions, non-profit organizations, and industry collaborators, will be able to access the de-identified individual participant data (IPD), provided they meet the necessary data use requirements. The available IPD will include the de-identified clinical and laboratory data collected throughout the study, such as demographic information, baseline clinical characteristics, treatment regimens, and efficacy and safety outcomes, including adverse events, pharmacokinetic data, and biomarker analyses. Data will be made available upon request through https://clinicalstudydatarequest.com/. Researchers wishing to access the data must submit a formal request, which will be evaluated based on the study's data sharing policies and relevant data use agreements.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2024, 2 months after the start.

Of 34 industry-sponsored phase 1 interventional studies under Epilepsy, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's planned 2 months is below that.

Counting every sponsor, half of 55 studies reached it within 8 months; a quarter within 3 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Jan 8, 2025
StartActual
Oct 21, 2024
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Jan 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06762743
Responsible party
Sponsor
First posted
Jan 8, 2025
Start date
Oct 21, 2024
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jan 8, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion